Alphatec secured exclusive U.S. rights to Theradaptive’s OsteoAdapt bone graft platform through a new partnership, according to a Jan. 12 news release.
Under the agreement Alphatec can market and distribute OsteoAdapt, a bone graft for spinal fusion, in the U.S. OsteoAdapt is an osteoinductive bone graft and is being evaluated in clinical trials for spine and dental use.
Theradaptive also launched a series B financing round to support clinical studies and scaling of OsteoAdapt.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.